New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePal-AHK vs Dulaglutide

Pal-AHK vs Dulaglutide

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Pal-AHK
GLP-1 / Weight Loss Agonists
Dulaglutide
Summary
Pal-AHK is the palmitoylated form of the AHK-Cu copper tripeptide, created by attaching a palmitic acid chain to enhance skin penetration and lipid bilayer affinity. The palmitoyl modification significantly improves dermal bioavailability compared to unmodified AHK, making it particularly effective in anti-aging and hair growth formulations.
Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
Half-Life
Extended (lipid depot effect in stratum corneum)
~5 days
Admin Route
Topical
SubQ
Research
Typical Dose
0.01–0.05% in formulation
0.75 mg → 1.5 mg
Frequency
Once or twice daily
Once weekly
Key Benefits
  • Enhanced skin penetration vs. unmodified AHK-Cu
  • Stimulates dermal collagen and elastin production
  • Promotes hair follicle anagen phase
  • Antioxidant and wound healing activity
  • Firming and plumping effect on aging skin
  • Improved bioavailability via lipid bilayer incorporation
  • FDA-approved for type 2 diabetes
  • Once-weekly subcutaneous dosing via auto-injector pen
  • Reduces HbA1c by approximately 1.1–1.6%
  • Modest weight loss of 1.5–3 kg at approved doses
  • Demonstrated cardiovascular risk reduction (REWIND trial)
  • Established long-term safety profile
  • Renal protective effects in CKD
Side Effects
  • Generally well-tolerated
  • Mild irritation at high concentrations in sensitive skin
  • Possible comedogenicity at very high palmitate concentrations (formulation-dependent)
  • Nausea (most common, typically transient)
  • Diarrhea
  • Vomiting
  • Decreased appetite
  • +3 more
Stacks With